^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lenvima (lenvatinib)

    i
    Other names: E7080, E-7080, E 7080, ER 20349200, ER-203492-00, MK-7902, ER20349200, ER-20349200, MK7902, MK 7902
    Company:
    Eisai, Knight Therap, Merck (MSD)
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    19h
    LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • letrozole
    20h
    CheckMate 9DW: A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Nov 2026 --> Jul 2026 | Trial primary completion date: Nov 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sorafenib • Lenvima (lenvatinib)
    1d
    Progress in management of advanced clear-cell renal cell carcinoma. (PubMed, Clin Transl Oncol)
    After prior ICI exposure, VEGFR-TKIs continue to represent the treatment backbone, while later-line options such as hypoxia-inducible factor-2α (HIF-2α) inhibitors and lenvatinib-everolimus further expand sequencing possibilities. Randomized studies have not shown consistent benefit for routine ICI rechallenge in unselected populations. Overall, advanced ccRCC management requires structured individualization, while validated predictive biomarkers and prospective sequencing data remain important unmet needs.
    Review • Journal • IO biomarker
    |
    EPAS1 (Endothelial PAS domain protein 1)
    |
    everolimus • Lenvima (lenvatinib)
    1d
    Synergistic Anticancer Effects of Lenvatinib Combined with N-butylidenephthalide in Human Colorectal Cancer Cells. (PubMed, Int J Med Sci)
    Furthermore, the combination treatment induced G2/M phase cell cycle arrest by modulating the ATM-Chk2 signaling pathway. This study demonstrates that the combination of lenvatinib and BP represents a promising therapeutic strategy for CRC by enhancing apoptosis and cell cycle arrest through ROS-mediated DNA damage.
    Journal
    |
    ANXA5 (Annexin A5) • H2AX (H2A.X Variant Histone)
    |
    Lenvima (lenvatinib)
    3d
    A novel diagnostic and prognostic biomarker FSD1L facilitates EMT and Lenvatinib resistance via the WNT/β-catenin pathway in hepatocellular carcinoma. (PubMed, Cell Signal)
    FSD1L is a novel oncogenic driver in HCC that is selectively enriched in metastatic and lenvatinib-resistant contexts. It activates the WNT/β-catenin pathway to regulate HCC proliferation, EMT and lenvatinib resistance. FSD1L holds promise as a dual biomarker for diagnosis/prognosis and a potential therapeutic target for lenvatinib resistance in HCC.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen)
    |
    Lenvima (lenvatinib)
    4d
    LONGIST: Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients (clinicaltrials.gov)
    P1/2, N=48, Recruiting, Asan Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • ANO1 (Anoctamin 1)
    |
    KIT mutation
    |
    imatinib • sunitinib • Lenvima (lenvatinib) • Stivarga (regorafenib)
    5d
    A case of poorly differentiated thyroid carcinoma harboring an SMARCB1 mutation. (PubMed, Int Cancer Conf J)
    Lenvatinib therapy was initiated at the previous hospital, resulting in tumor shrinkage, and total thyroidectomy was performed 62 days after the initiation of treatment...We report a case of poorly differentiated thyroid carcinoma with an SMARCB1 mutation. The accumulation of similar cases and additional immunohistochemical evaluations of past specimens may contribute to the development of targeted therapeutic strategies.
    Journal
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Lenvima (lenvatinib)
    5d
    Resistance by Inhibiting the STAT3/SLC25A27 Pathway and Promoting Ferroptosis in Hepatocellular Carcinoma. (PubMed, Curr Cancer Drug Targets)
    Moreover, artesunate promotes ferroptosis by inhibiting the STAT3/SLC25A27/ SLC7A11/GPX4 axis in vivo and in vitro. Overall, our study confirmed the combination of artesunate and lenvatinib significantly enhances the anti-HCC effect of lenvatinib, which promising therapeutic strategy to circumvent resistance in HCC.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    Lenvima (lenvatinib)
    5d
    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov)
    P2, N=39, Recruiting, Peking Union Medical College | Trial primary completion date: Jul 2026 --> Jul 2028
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    carboplatin • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lenvima (lenvatinib) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Piqray (alpelisib) • Irene (pyrotinib) • albumin-bound paclitaxel • abiraterone acetate • fulvestrant • Aidixi (disitamab vedotin) • exemestane • Padcev (enfortumab vedotin-ejfv) • bicalutamide • Kaitanni (cadonilimab) • goserelin acetate • Qibeian (iparomlimab/tuvonralimab) • Yidafan (ivonescimab) • iparomlimab (QL1604) • leuprolide acetate for depot suspension • Entyvio (vedolizumab)
    6d
    Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma. (clinicaltrials.gov)
    P2, N=36, Completed, Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial completion date
    |
    Lenvima (lenvatinib) • Tevimbra (tislelizumab-jsgr)
    7d
    Neoadjuvant Therapies for Thyroid Cancer: A Scoping Review. (PubMed, Laryngoscope)
    Neoadjuvant therapy shows promise in improving resectability for unresectable and poorly differentiated thyroid cancers, with 51% of patients achieving R0 resection. Future studies should investigate optimal therapy selection, timing, dosing, and long-term outcomes, including disease-specific survival and patient-reported measures.
    Review • Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • BRAF V600E • BRAF V600
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Lenvima (lenvatinib)
    7d
    Identification of a small-molecule targeting PLAGL2 DNA-binding domain inhibits extracellular matrix formation and enhances lenvatinib sensitivity in hepatocellular carcinoma. (PubMed, Acta Pharm Sin B)
    DC218 significantly degraded ECM, overcame lenvatinib resistance, and synergistically inhibited HCC. These findings provide mechanistic insight into the role of PLAGL2 in HCC ECM remodeling, as well as suggest a novel strategy for inhibiting ECM and treating HCC.
    Journal
    |
    IGF2 (Insulin-like growth factor 2) • PLAGL2 (PLAG1 Like Zinc Finger 2)
    |
    Lenvima (lenvatinib)